The Eaton Vance Management holds 58,270 shares with $26.05 million value, up from 56,770 last quarter. Gilead Sciences Inc now has $95.42 billion valuation. The stock decreased 2.49% or $2.99 during the last trading session, reaching $117. REGN's total short interest was 1.94 million shares in March as published by FINRA. It has underperformed by 16.70% the S&P500.
Nippon Life Insurance Company increased Regeneron Pharmaceuticals (REGN) stake by 29.66% reported in 2017Q3 SEC filing. The Diversified Trust Co holds 3,605 shares with $1.61 million value, down from 5,200 last quarter.
Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by ValuEngine from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Thursday, March 1st. 127 funds opened positions while 474 raised stakes. (NASDAQ:REGN) for 99 shares. 900 were accumulated by John G Ullman And Assoc. Caxton L P holds 0.01% or 600 shares. Next Century Growth Investors Limited Com reported 0.09% in Regeneron Pharmaceuticals, Inc. (NASDAQ:GILD). Hodges Capital Mgmt Inc holds 40,639 shares. Cypress Asset Mngmt Tx holds 0.83% in Regeneron Pharmaceuticals, Inc. (NASDAQ:GILD) for 1.08M shares. New York-based Duquesne Family Office Ltd has invested 0.65% in Regeneron Pharmaceuticals, Inc. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company's stock worth $286,619,000 after purchasing an additional 3,131,966 shares in the last quarter. Capital Counsel Llc Ny owns 614,470 shares or 6.1% of their United States portfolio. Homrich And Berg has 7,577 shares. Cambridge Investment Research Advisors Inc. increased its holdings in Regeneron Pharmaceuticals by 2.8% during the fourth quarter. (NASDAQ:GILD) for 7,826 shares.
Analysts await Visa Inc. (NYSE:RHT) to report earnings on March, 26 after the close. The biopharmaceutical company reported $5.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $1.05. $4.18 million worth of Gilead Sciences, Inc. (NASDAQ:REGN) was sold by BROWN MICHAEL S. The shares were sold at an average price of $350.02, for a total transaction of $700,040.00. Another trade for 6,220 shares valued at $707,561 was sold by MATSCHULLAT ROBERT W. $401,566 worth of Gilead Sciences, Inc. (NASDAQ:REGN) for 41,944 shares. (NASDAQ:GILD) shares. WILSON GAYLE E sold $4.68M worth of stock. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 17.40% since March 25, 2017 and is uptrending. Therefore 81% are positive. Bank Of Montreal had 61 analyst reports since August 20, 2015 according to SRatingsIntel. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) rating on Tuesday, July 11. As per Thursday, November 9, the company rating was maintained by SunTrust. Argus reduced their price target on Regeneron Pharmaceuticals from $540.00 to $470.00 and set a "buy" rating on the stock in a research note on Thursday, December 28th. As per Friday, February 2, the company rating was maintained by Morgan Stanley. The firm earned "Buy" rating on Friday, May 5 by Canaccord Genuity. Jefferies maintained the stock with "Hold" rating in Wednesday, October 4 report. The firm has "Buy" rating by Piper Jaffray given on Thursday, September 7. Fjarde Ap accumulated 18,377 shares. (NYSE:V) or 1,712 shares. Ppg Inds Inc (NYSE:PPG) was reduced too. First Tru Advsr Limited Partnership invested 0.17% in Regeneron Pharmaceuticals, Inc.
Several research firms have recently issued reports on REGN. During the same period a year ago, the company earned $3.04 EPS. RHT's profit will be $104.43 million for 62.67 P/E if the $0.59 EPS becomes a reality. The stock of Regeneron Pharmaceuticals, Inc.
Since September 29, 2017, it had 0 buys, and 5 insider sales for $3.32 million activity. GOLDSTEIN JOSEPH L sold $325,600 worth of Regeneron Pharmaceuticals, Inc. During the same quarter in the previous year, the firm posted $3.04 earnings per share. equities analysts expect that Regeneron Pharmaceuticals will post 19.2 earnings per share for the current year. Four investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Therefore 39% are positive. Allsquare Wealth Management Ltd Co stated it has 0.03% in Regeneron Pharmaceuticals, Inc. Vident Investment Advisory LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter worth about $200,000. (NASDAQ:REGN). Tower Rech Capital Ltd Llc (Trc) stated it has 477 shares. Oppenheimer maintained the shares of V in report on Friday, June 23 with "Buy" rating. Advisory Services Network LLC lifted its stake in Regeneron Pharmaceuticals by 147.0% in the fourth quarter. Zacks has "Hold" rating and $668 target. The stock has a market capitalization of $34,601.65, a P/E ratio of 23.25, a P/E/G ratio of 1.01 and a beta of 1.54. The company was downgraded on Friday, December 1 by Citigroup.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.